Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19 Feb 22, 2021 07:30AM
Biohaven Pharma (BHVN) Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs Jan 7, 2021 07:37AM
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs Jan 7, 2021 07:30AM
Kleo Pharmaceuticals Inc. Appoints David A. Spiegel as Chief Executive Officer Sep 22, 2016 03:00AM